New combo aims to outsmart resistant breast cancer
NCT ID NCT07395336
First seen Feb 10, 2026 · Last updated May 09, 2026 · Updated 11 times
Summary
This phase 2 trial tests a combination of two hormone therapies (elacestrant and exemestane) in 26 people with advanced HR+/HER2- breast cancer whose disease has progressed after initial treatment. The study uses a special PET scan to select participants whose tumors still have active estrogen receptors. The goal is to see if this combination can control the cancer for at least 6 months without the need for chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.